Sugi Predict

Sugi Predict / Compounds / SCHEMBL29461455

SCHEMBL29461455

SCHEMBL29461455

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)O

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 16/20 0.56
▸ VIPR2 P41587 3/20 0.53
▸ VIPR1 P32241 3/20 0.53
▸ SCTR P47872 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31353031 0.92 GLP1R (0.51) GLP1RVIPR1SCTR
SCHEMBL30150658 0.90 GLP1R (0.49) GLP1RVIPR2VIPR1
SCHEMBL30887565 0.89 KISS1R (0.51) GLP1RVIPR2VIPR1
SCHEMBL30495723 0.88 VIPR1 (0.69) GLP1RVIPR2VIPR1SCTR
SCHEMBL30415618 0.88 VIPR1 (0.53) GLP1RVIPR2VIPR1SCTR
SCHEMBL30369010 0.88 GLP1R (0.45) GLP1RVIPR2VIPR1
SCHEMBL31366748 0.88 GLP1R (0.51) GLP1RVIPR2VIPR1SCTR
SCHEMBL30483960 0.87 GLP1R (0.52) GLP1RVIPR2VIPR1SCTR
SCHEMBL29871041 0.87 GLP1R (0.59) GLP1RSCTR
SCHEMBL31183012 0.87 VIPR1 (0.62) GLP1RVIPR2VIPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12629409-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2026-05-19 — — US disclosed
US-20240226261-A9 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-07-11 — — US disclosed
US-20240131136-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2024-04-25 — — US disclosed
US-11844828-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-12-19 — — US disclosed
US-20230248816-A9 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-08-10 — — US disclosed
US-20230066762-A1 IMMUNOGENIC COMPOSITION GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-03-02 — — US disclosed
US-20220288190-A1 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-09-15 — — US disclosed
US-20220152182-A1 VACCINE GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-05-19 — — US disclosed
US-11266731-B2 Vaccine GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-03-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220288190-A1 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CFD, PEPD, SERPINA6 GLP1R 2107/4885VIPR2 860/4885VIPR1 814/4885
US-20230248816-A9 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE CFD, PEPD, SERPINA6 GLP1R 2107/4885VIPR2 860/4885VIPR1 814/4885
US-12629409-B2 Vaccine MRPL21, STT3B, CD47 GLP1R 1475/4885VIPR2 3765/4885VIPR1 3836/4885
US-20230066762-A1 IMMUNOGENIC COMPOSITION CXCL10, CCL2, CCL11 GLP1R 2834/4885VIPR2 1911/4885VIPR1 1718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback